Metastatic ovarian, prostate and breast cancers are notoriously difficult to treat and often deadly. Now, researchers have revealed a new role for the CDK12 protein.

Metastatic ovarian, prostate and breast cancers are notoriously difficult to treat and often deadly. Now, Salk Institute researchers have revealed a new role for the CDK12 protein. The findings ...

Yu Chang et al, Development of an orally bioavailable CDK12/13 degrader and induction of synthetic lethality with AKT pathway inhibition, Cell Reports Medicine (2024).DOI: 10.1016/j.xcrm.2024.101752 ...

The team noted lower cell viability in the CDK12KO organoids after treatment with the CD12/13 degrader, YJ9069. CDK12/13 degradation inhibited the protein kinase B (AKT) pathway.

Researchers previously found loss of the CDK12 gene in about 7% of patients with metastatic prostate cancer, suggesting this alteration may be linked to a more-aggressive form of the disease.

CDK12 is known to play a role in about 7% of metastatic prostate cancers and about 3% of tubo-ovarian high-grade serous cancers. It has not been shown to be inactivated in other cancer types.

Again, while not possible to target CDK12, its counterpart of RBM39 might be. As far as the development of REC-994 being used for the treatment of patients with CCM goes, this remains a toss-up.

Syros to Present New Preclinical Data on its CDK12 Inhibitor Program at the American Association for Cancer Research (AACR) Annual Meeting 2022. March 08, 2022 04:31 PM Eastern Standard Time.

CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13. Cell Reports Medicine , 2024; 101758 DOI: 10.1016/j.xcrm.2024.101758 ...

By Pooja Toshniwal Paharia Breakthrough research sheds light on the genetic mutation behind aggressive prostate cancer. Study: CDK12 loss drives prostate cancer progression, transcription ...